London, United Kingdom
Vantage Biosciences, founded in 2023, is a promising clinical stage biotechnology company based in the United Kingdom. Specializing in addressing the root causes of diabetic eye disease, Vantage focuses on the neuroinflammatory processes that trigger microangiopathy and the subsequent degeneration of the neurovascular unit in the eye.
By working toward an innovative oral treatment solution, Vantage aims to transform how diabetic eye disease is managed, offering a proactive, disease-modifying approach that intervenes early in disease progression. Their slogan, "Transforming diabetic eye disease with an oral treatment," encapsulates this mission.
Operating primarily in the Biotechnology and Health Care sectors, the company received its last investment as a Seed investment on 01 January 2023 from ALSA Ventures. This support underscores investor confidence in Vantage's innovative approach and potential impact on health and wellness.
